“…Experiments have demonstrated that exosomes derived from BMSCs provide a safeguard against bortezomib by activating certain proteins (c-Jun, p38, p53, AKT) and influencing the expression of Bcl-2, caspase 9, caspase 3, and PARP [ 145 ]. In addition, exosomes have the ability to influence the immune response in the BMME, creating a suppressive environment that enables myeloma cells to avoid detection by the immune system and continue to survive even after treatment [ 146 ]. Furthermore, exosomes play a role in the survival of MDSCs by activating STAT3 and enhancing their immunosuppressive characteristics [ 147 , 148 ].…”